Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

Abstract Background Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationship...

Full description

Bibliographic Details
Main Authors: Robert P. Cowan, Michael J. Marmura, Hans-Christoph Diener, Amaal J. Starling, Jack Schim, Joe Hirman, Thomas Brevig, Roger Cady
Format: Article
Language:English
Published: BMC 2022-09-01
Series:The Journal of Headache and Pain
Subjects:
Chronic migraine
Eptinezumab
Medication-overuse headache
Serotonin 5-HT1 receptor agonists
Analgesics
Online Access:https://doi.org/10.1186/s10194-022-01482-0

Internet

https://doi.org/10.1186/s10194-022-01482-0

Similar Items